CLOBUTINOL HCL
Get in touch with us!
An overview
Symptomatic treatment of cough reflex and non-productive cough in inflammatory disorders of the respiratory tract due to infection or other causes, smoker’s cough. It is effective in suppression of irritative cough during or after surgical, endoscopic, radiological or thoracentesis procedures. Irritative cough after endotracheal intubation or postoperative.
- Product Type: Non-opioid antitussive agent
- CAS Number: 1215-83-4
- Common Indications: Cough suppressants and associations with expectorants.
- Product Status: Commercial
- Available Grades: Non-Micronized
- Documentation: DMF, CoA, MSDS
Advantages
Efficacy:
Much higher therapeutic adherence
Very wide antibiotic spectrum of action
Activity against Neisseria meningitidis.
Used to treat multidrug-resistant.
Safety:
Better pharmacokinetic profile.
Longer half-life than Tetracycline.
FDA and European approval for the treatment of infections.
Low development of resistance in bacteria.
Finished
Dosage Forms
Oral:
Coated tablets:
40 mg
Syrup:
20 mg/5 ml
Global market status
USD global market sales in 2023
consumed globally
Lorem ipsum solor
Few API manufacturers to cover worldwide demand.
Our API
Clobutinol
- Our API Clobutinol is manufactured in accordance with cGMP and stringent international quality standards.
Quality
- Our quality control follows every stage from development of analytical methods to the control of manufacturing process.
Samples availables
PATENT PROTECTION
